# Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

> **NCT06510309** · PHASE2 · RECRUITING · sponsor: **Gottfried von Keudell, MD PhD** · enrollment: 33 (estimated)

## Conditions studied

- Lymphoma
- Marginal Zone Lymphoma
- MZL

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT06510309
- **Lead sponsor:** Gottfried von Keudell, MD PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-11
- **Primary completion:** 2028-10
- **Final completion:** 2031-10-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06510309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06510309, "Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06510309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*